{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:03:58Z","timestamp":1767135838148,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd009806","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T00:00:00Z","timestamp":1457049600000}}],"reference-count":41,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009806.pub2","type":"journal-article","created":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T14:15:03Z","timestamp":1457273703000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI"],"prefix":"10.1002","author":[{"given":"Marcela Junqueira","family":"Brunelli","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Dr Wladimir dos Santos Mello 122 S\u00e3o Paulo S\u00e3o Paulo Brazil 04112-030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro N","family":"Atallah","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Brazilian Cochrane Centre; R. Borges Lagoa, 564 cj 63 Vila Clementino S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edina MK","family":"da Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Emergency Medicine and Evidence Based Medicine; Rua Borges Lagoa 564 cj 64 Vl. Clementino S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,4]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009806.pub2-BIB0002|cit2","first-page":"190, Abstract n","article-title":"A phase 3, randomized, double-blind, placebo-controlled, multicenter, multinational clinical study of recombinant human N-acetylgalactosamine 4 sulfatase (rhASB) in patients with mucopolysaccharidosis VI [abstract]","volume":"28","author":"Guffon","year":"2005","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD009806.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009806.pub2-BIB0004|cit4","first-page":"29, Abstract no","article-title":"Long term benefit and safety with recombinant human arylsulfatase B (rhASB) ERT for MPS VI [abstract]","volume":"29","author":"Harmatz","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"4","key":"10.1002\/14651858.CD009806.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Molecular Genetics and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD009806.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study","volume":"148","author":"Harmatz","year":"2006","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD009806.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","article-title":"Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively","volume":"31","author":"Bagewadi","year":"2008","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009806.pub2-BIB0009|cit9","first-page":"183, Abstract n","article-title":"Update on clinical trial results in MPS VI [abstract]","volume":"27","author":"Harmatz","year":"2004","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"4","key":"10.1002\/14651858.CD009806.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Molecular Genetics and Metabolism"},{"issue":"447","key":"10.1002\/14651858.CD009806.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/08035320510028139","article-title":"Mucopolysaccharidosis VI Study Group. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I\/II study","volume":"94","author":"Harmatz","year":"2005","journal-title":"Acta Paediatrica Supplement"},{"issue":"5","key":"10.1002\/14651858.CD009806.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009806.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"7","key":"10.1002\/14651858.CD009806.pub2-BIB0014|cit14","first-page":"776","article-title":"Enzyme replacement therapy for the mucopolysaccharidoses [abstract]","volume":"14","author":"Kakkis","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD009806.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/humu.10313","article-title":"Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy","volume":"23","author":"Karageorgos","year":"2004","journal-title":"Human Mutation"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009806.pub2-BIB0017|cit17","first-page":"183, Abstract n","article-title":"Update on clinical trial results in MPS VI [abstract]","volume":"27","author":"Harmatz","year":"2004","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"4","key":"10.1002\/14651858.CD009806.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Molecular Genetics and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD009806.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1542\/peds.2004-1023","article-title":"Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine4-sulfatase","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009806.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","article-title":"Galsulfase (Naglazyme(R)) therapy in infants with mucopolysaccharidosis VI","volume":"37","author":"Harmatz","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"7","key":"10.1002\/14651858.CD009806.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00417-008-1030-1","article-title":"Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?","volume":"247","author":"Pitz","year":"2009","journal-title":"Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie [Graefe's Archive for Clinical and Experimental Ophthalmology]"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0024|cit24","first-page":"130","article-title":"Mucopolysaccharidosis type VI (Maroteaux-Lamysyndrome): assessment of joint mobility and grip and pinch strength","volume":"84","author":"Cardoso-Santos","year":"2008","journal-title":"Jornal of Pediatrica"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/PRM-2010-0113","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"3","author":"Decker","year":"2010","journal-title":"Journal of Pediatric Rehabilitation Medicine"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0026|cit26","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org","author":"Deeks","year":"2011"},{"issue":"7","key":"10.1002\/14651858.CD009806.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0960327110379023","article-title":"Thrombocytopenia associated with galsulfase treatment","volume":"30","author":"Do\u011fan","year":"2011","journal-title":"Human & Experimental Toxicology"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0028|cit28","first-page":"459-68","article-title":"A systematic review of new advances in the management of mucopolysaccharidosisVI (Maroteaux-Lamy syndrome): focus on galsulfase","volume":"3","author":"Dib","year":"2009","journal-title":"Biologics"},{"issue":"1","key":"10.1002\/14651858.CD009806.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne\u00a0DR","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD009806.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1953-1964","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study","volume":"164","author":"Giugliani","year":"2014","journal-title":"Am J Med Genet Part A"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0032|cit32","first-page":"555","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins\u00a0JPT","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0033|cit33","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org","author":"Higgins","year":"2011"},{"issue":"3","key":"10.1002\/14651858.CD009806.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00206770","article-title":"An update on the frequency of mucopolysaccharide syndromes in British Columbia","volume":"85","author":"Lowry","year":"1990","journal-title":"Human Genetics"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0035|cit35","first-page":"1849","article-title":"A new dysostosis with urinary elimination of chondroitin sulfate B","volume":"71","author":"Maroteaux","year":"1963","journal-title":"Presse Medicale"},{"issue":"3","key":"10.1002\/14651858.CD009806.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD009806.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","article-title":"Incidence of the mucopolysaccharidoses in Northern Ireland","volume":"101","author":"Nelson","year":"1997","journal-title":"Human Genetics"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0038|cit38","first-page":"3421","article-title":"The Mucopolysaccharidoses","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","volume":"3","author":"Neufeld","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD009806.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"European Journal of Human Genetics"},{"key":"10.1002\/14651858.CD009806.pub2-BIB0040|cit40","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"5","key":"10.1002\/14651858.CD009806.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"12","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet Journal of Rare Disease"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009806.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009806.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:16:52Z","timestamp":1748783812000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009806.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,4]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009806.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,4]]}}}